The prognostic value of plasma galectin-3 in chronic heart failure patients treated with mineralocorticoid receptor antagonists

被引：0
作者：
Rouet, P. [1 ]
Koukoui, F. [1 ]
Desmoulin, F. [1 ]
Barutaut, M. [1 ]
Caubere, C. [1 ]
Berry, M. [2 ]
Evaristi, M. [1 ]
Smih, F. [1 ]
Galinier, M. [2 ]
机构：
[1] UPS, INSERM, I2MC, U1048, Toulouse, France
[2] Univ Hosp Toulouse, Rangueil Hosp, INSERM, UPS,U1048, Toulouse, France
来源：
EUROPEAN HEART JOURNAL | 2014年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P3674
引用
收藏
页码：673 / 673
页数：1
相关论文
共 50 条
  • [41] Biological variability of galectin-3 in chronic heart failure
    Piper, SSusan
    Hipperson, D.
    Decourcey, J.
    Sherwood, R.
    Amin-Youssef, G.
    Shah, A.
    Mcdonagh, T. A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2014, 16 : 177 - 177
  • [42] Mineralocorticoid receptor antagonists for heart failure
    Funder, John
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (18) : 2767 - 2769
  • [43] Prognostic value of galectin-3 in adults with congenital heart disease
    Baggen, Vivan J. M.
    van den Bosch, Annemien E.
    Eindhoven, Jannet A.
    Menting, Myrthe E.
    Witsenburg, Maarten
    Cuypers, Judith A. A. E.
    Boersma, Eric
    Roos-Hesselink, Jolien W.
    HEART, 2018, 104 (05) : 394 - 400
  • [44] sST2 adds to the prognostic value of Gal-3 and BNP in chronic heart failure, independent of Mineralocorticoid Receptor Antagonists treatment
    Barutaut, M.
    Fournier, P.
    Peacock, W. F.
    Dambrin, C.
    Caubere, C.
    Servoz, C.
    Koukoui, F.
    Galinier, M.
    Smih, F.
    Rouet, P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 241 - 242
  • [45] Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study
    Lok, Dirk J. A.
    Van Der Meer, Peter
    Bruggink-Andre de la Porte, Pieta W.
    Lipsic, Erik
    Van Wijngaarden, Jan
    Hillege, Hans L.
    van Veldhuisen, Dirk J.
    CLINICAL RESEARCH IN CARDIOLOGY, 2010, 99 (05) : 323 - 328
  • [46] Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study
    Dirk J. A. Lok
    Peter Van Der Meer
    Pieta W. Bruggink-André de la Porte
    Erik Lipsic
    Jan Van Wijngaarden
    Hans L. Hillege
    Dirk J. van Veldhuisen
    Clinical Research in Cardiology, 2010, 99 : 323 - 328
  • [47] Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease
    Khan, Mohammad Saud
    Khan, Muhammad Shahzeb
    Moustafa, Abdelmoniem
    Anderson, Allen S.
    Mehta, Rupal
    Khan, Sadiya S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 125 (04) : 643 - 650
  • [48] Study of the effectiveness of mineralocorticoid receptor antagonists on neurohumoral parameters in patients with chronic heart failure
    Kamilova, U. Umida
    Nuritdinov, N.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 : 361 - 361
  • [49] Mineralocorticoid receptor antagonists in the treatment of patients with chronic heart failure. Positions in 2015
    Osmolovskaya, Yu. F.
    Zhirov, I. V.
    Tereshchenko, S. N.
    TERAPEVTICHESKII ARKHIV, 2015, 87 (09) : 77 - 83
  • [50] Prognostic value of galectin-3 and right ventricular function for long-term mortality in heart failure patients treated with cardiac resynchronization therapy
    Zaborska, Beata
    Pilichowska-Paszkiet, Ewa
    Makowska, Ewa
    Sygitowicz, Grazyna
    Slomski, Tomasz
    Zaborski, Michal
    Budaj, Andrzej
    SCIENTIFIC REPORTS, 2021, 11 (01)
12345